GAiT is an international resource to facilitate the therapeutic use of immunogenetically matched, clinical-grade new types of stem cells (iPSCs) for the benefit of patients globally. GAiT’s vision is that patients globally will have equity of access to this new generation of iPSC-derived cell therapy products.
GAiT’s mission is to enable the global human community the opportunity to benefit from the new generation of cell therapies by facilitating the development of, and access to, clinical-grade and haplotyped induced pluripotent stem cells for the manufacture of cell therapy products.
- Achieve consensus on donor selection and screening criteria and consent standards.
- Achieve global consensus on manufacturing and quality parameters and standards required to consider an iPSC line to be of clinical grade and develop an external quality assurance scheme to facilitate the development of comparability between centres.
- Gain agreement with regulators in various jurisdictions as to the acceptability of the quality standards proposed.
- Develop a database of clinical grade iPSC lines.
News & Events
The latest from GAiT
Thanks to all iPSC Quality Assessment Round Participants for their discussion of the amalgamated datasets during the Quality Workshop earlier today.
Workshop materials were sent to Participants for the iPSC Quality Assessment Round next Monday. Participants can leave comments or questions on the slides themselves that will be addressed during the Workshop.
A Quality Round Virtual Workshop has been scheduled for Monday, 14th September. Participants were sent invitations today.
GAiT discusses Quality and Standards for efficient iPSC Therapeutic Development at Biotechne's 2nd ATMP Virtual Symposium. Join live Q&A or listen to recording here. https://info.bio-techne.com/WBNBIO-TECHNE-2020-07webinar-AnalysingATMPS_LP-webinar-main.html
@HCATS_CDMO @IPSCtherapies @PaceLabs @synthace @CCRM_ca @ProteinSimple https://twitter.com/biotechne/status/1278725382695538689
Fate Therapeutics (@FateThx) has received FDA clearance of their IND application for the first-ever #iPSC-derived CAR T-Cell Therapy.
Congratulations to Susan Solomon, GAiT Director and CEO of @NYSCF, for winning the @ISSCR Stem Cell Public Service Award
Susan L. Solomon Receives Public Service Award From International Society for Stem Cell Research - New York Stem Cell Foundation
NYSCF CEO Susan L. Solomon recently received the 2020 Public Service Award from the International Society for Stem Cell...